| Name | Title | Contact Details |
|---|
PMC Associates is a family-owned and operated technology integrator, specializing in Two-Way Radio Systems and Subscribers, as well as other Mission-Critical Communications equipment. Founded in 1988, and located in Hazlet, New Jersey, PMC serves the NYC Metropolitan area, as well as upstate NY, NJ, PA, DE, MD, DC and VA.
Jenius Bank is a digital banking service provided by Bank SMBC Indonesia, a subsidiary of Sumitomo Mitsui Banking Corporation. It aims to redefine banking by offering better rates on financial products and personalized insights for effective financial management. The Jenius app integrates a variety of services, including money transfers, QR code payments, asset management, investment options, credit card services, and lending solutions. The Jenius Main Debit Card (m-Card) features a modern design and aligns with the companys "Think Unthinkable" philosophy. Jenius primarily targets millennials and has attracted over 5.2 million customers in Indonesia, appealing to those seeking a user-friendly banking experience. Customers who receive their paychecks through Jenius enjoy benefits like free remittance fees and withdrawal services. Jenius is committed to helping users organize their finances and encourages innovative thinking in the banking sector. Recent updates, including a new booth concept and a redesigned debit card, reflect its dedication to enhancing customer experience.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.